Comment: A commenter mentioned our proposed regulation text edits and noted that the changes discussed in the preamble did not align with what was included in the regulation text at the end of the proposed rule and suggested that there may have been an inadvertent drafting error
HCC / Risk Adjustment (v28) HCC mappings below reflect CMS-HCC Model v28 (CY2026 MA risk adjustment)
Who Should Avoid MOTS-c Pregnant or breastfeeding individuals People with an active cancer diagnosis, since MOTS-c may affect prostate and breast cancer pathways Those taking AMPK-activating medications like metformin, thiazolidinediones, or aspirin Anyone on insulin or with uncontrolled diabetes without medical supervision Minors and adolescents Athletes in tested sports, since MOTS-c is on the WADA Prohibited List under Section S4 Anyone without access to lab-verified research peptides MOTS-c vs Other Metabolic Peptides (High-Level Comparison) MOTS-c vs Semaglutide MOTS-c works through the mitochondrial pathway with gradual, muscle-preserving results
The tirzepatide shelf life depends on formulation type and storage conditions, and exceeding recommended storage times can result in degraded peptide that does not perform as expected
Where is the best place to inject Zepbound
doi: 10.1016/B978-0-12-416673-8.00009-5 [DOI] [PubMed] [Google Scholar] 37.Danaei M, Dehghankhold M, Ataei S, et al